Free Trial

EyePoint Pharmaceuticals (EYPT) Earnings Date, Estimates & Call Transcripts

EyePoint Pharmaceuticals logo
$5.86 -0.35 (-5.64%)
As of 11:20 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals Earnings Summary

EyePoint Pharmaceuticals posted Q1 2025 earnings on May 7, 2025, reporting an EPS of -$0.65, which hit the consensus estimate of -$0.65. Quarterly revenue was reported to be $24.50 million, above analysts' expectations of $8.84 million. With a trailing EPS of -$2.41, EyePoint Pharmaceuticals' earnings are expected to decrease next year, from ($2.13) to ($2.52) per share.

Upcoming Q2
Earnings Date
Aug. 6Before Market OpensEstimated
Consensus EPS
(May. 7)
-$0.65
Actual EPS
(May. 7)
-$0.65
Actual Revenue
(May. 7)
$24.50M

Q1 2025 Earnings Resources

EYPT Upcoming Earnings

EyePoint Pharmaceuticals' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules.

Get EyePoint Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on EyePoint Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

EYPT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

EYPT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

EyePoint Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20251-$0.63-$0.63-$0.63
Q2 20251-$0.63-$0.63-$0.63
Q3 20251-$0.78-$0.78-$0.78
Q4 20251-$0.78-$0.78-$0.78
FY 2025 4 -$2.82 -$2.82 -$2.82
Q1 20261-$0.74-$0.74-$0.74
Q2 20261-$0.74-$0.74-$0.74
Q3 20261-$0.74-$0.74-$0.74
Q4 20261-$0.67-$0.67-$0.67

EyePoint Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/6/2025
(Estimated)
--------
5/7/2025Q1 2025-$0.65-$0.65--$0.65$8.84M$24.50M
3/5/2025Q4 2024-$0.54-$0.64 -$0.10-$0.64$11.02M$11.60M
11/7/2024--$0.48-$0.54 -$0.06-$0.54$12.35M$10.52M
8/7/2024--$0.55-$0.58 -$0.03-$0.58$11.61M$9.48M
5/8/2024Q1 2024-$0.34-$0.55 -$0.21-$0.55$12.50M$11.68M
3/7/2024Q4 2023-$0.60-$0.33+$0.27-$0.33$8.71M$14.03M
11/1/2023Q3 2023-$0.62-$0.33+$0.29-$0.33$3.90M$15.20M
8/2/2023Q2 2023$0.41-$0.61 -$1.02-$0.61$79.03M$9.11M

EyePoint Pharmaceuticals Earnings - Frequently Asked Questions

EyePoint Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on EYPT's earnings history.

In the previous quarter, EyePoint Pharmaceuticals (NASDAQ:EYPT) reported ($0.65) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.65). Learn more on analysts' earnings estimate vs. EYPT's actual earnings.

The conference call for EyePoint Pharmaceuticals's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for EyePoint Pharmaceuticals's latest earnings report can be read online.
Read Transcript

EyePoint Pharmaceuticals (NASDAQ:EYPT) has a recorded annual revenue of $56.04 million.

EyePoint Pharmaceuticals (NASDAQ:EYPT) has a recorded net income of -$70.79 million. EYPT has generated -$2.41 earnings per share over the last four quarters.

EyePoint Pharmaceuticals's earnings are expected to decrease from ($2.13) per share to ($2.52) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:EYPT) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners